ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1649947
This article is part of the Research TopicRodent Model Organisms: Therapeutic Treatments and Drugs Interaction with the Gut Microbiome, Volume IIView all 10 articles
Regulatory Effects of Berberine on Intestinal Microecology in Mice with Ulcerative Colitis
Provisionally accepted- 1Graduate School of Shanghai Medical College, Fudan University, Shanghai 200032, China
- 2Chongqing Shapingba Hospital of Traditional Chinese Medicine, Chongqing 400030, China
- 3Nanjing University of Chinese Medicine, Nanjing 210023, China
- 4Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Methods: A mouse UC model was established via dextran sulfate sodium (DSS) induction, and dose-and time-dependent screening was performed to determine the optimal BBR dosage and intervention duration for subsequent experiments. The disease activity index (DAI) and colon length were measured. Colonic tissue changes were observed via HE staining. Serum cytokine levels (IL-1β, TNF-α, IL-10, TGF-β) were detected using ELISA. The expression levels of ZO-1 and Occludin in mouse colonic tissues were detected by WB. Further analyses included 16S rRNA sequencing to assess gut microbiota diversity and composition, untargeted metabolomics to identify differential metabolites in intestinal tissues, and Mendelian randomization (MR) analysis to explore causal associations among intestinal genes, circulating metabolites, and key bacterial genera. Finally, functional validation was performed by inhibiting the PDGFA receptor. Results: Berberine significantly alleviated the DAI score, colonic pathological damage, and cytokine imbalance in UC mice, as well as restored mucosal barrier integrity, with the most pronounced effects observed in the UC+low-BBR 14 days group. Gut microbiota analysis revealed distinct microbial structures across groups, with the UC+low-BBR 14 days group showing significantly higher relative abundances of Bacteroides, Alistipes, and unclassified_Clostridia_vadinBB60_group compared to the UC group (p < 0.05). Metabolomics analysis indicated that berberine altered the composition of intestinal tissue metabolites and metabolic pathways. MR analysis demonstrated inverse causal associations between PDGFA and lithocholate sulfate, as well as between lithocholate sulfate and Alistipes. Additionally, inhibition of the PDGFA receptor reversed the therapeutic effects of BBR, exacerbating inflammatory responses and intestinal mucosal barrier damage. Finally, the correlation analysis between gut microbiota and metabolites also confirmed that the abundance of the genus Alistipes exhibited a highly significant negative correlation with lithocholate sulfate levels (p < 0.001). Conclusion: Berberine ameliorates symptoms of UC in mice by regulating gut microbiota and metabolite composition. MR analysis first establishes a unidirectional causal chain of PDGFA / lithocholate sulfate / Alistipes, and animal experiments confirm that blocking the PDGFA receptor reverses its therapeutic effects and aggravates inflammation and intestinal mucosal injury.
Keywords: Berberine, ulcerative colitis, Gut Microbiota, Metabolites, Mendelian randomization
Received: 19 Jun 2025; Accepted: 21 Oct 2025.
Copyright: © 2025 Xu, Zhao, Liu, Tang, Lai, Song and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Na Song, songna896600@163.com
Jun Cheng, 13206075951@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.